ImmunityBio Acquires U.S. Rights to Tokyo Strain BCG for $60M
0h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
immunitybiobcg-immunotherapy
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
ImmunityBio announced on 16 May 2026 that it will acquire exclusive U.S. rights to the Tokyo-172 strain of the Bacillus Calmette-Guérin (BCG) vaccine from a Japanese partner. The transaction is valued at $60 million and is structured as an upfront payment. This acquisition secures a critical manufacturing component for the company's lead investigational immunotherapy, N-803, which is being developed in combination with BCG for the treatment of non-muscle invasive bladder cancer (NMIBC). The deal is expected to close in the third quarter of 2026.
The global supply of the BCG vaccine has been constrained for years, with Merck's TICE strain being the only FDA-approved product for bladder cancer. A severe shortage was declared by the FDA in 2019, lasting over four years and forcing clinicians to ration treatment. This scarcity created a significant unmet need for reliable, effective alternatives for NMIBC, a market projected to reach $1.8 billion by 2028.
The current macro backdrop for biotech is characterized by a cautious Federal Reserve, with the benchmark rate holding at 5.25%. The XBI biotech ETF is down 4% year-to-date, reflecting a challenging environment for funding and growth. ImmunityBio's move is a direct response to the persistent supply issues, securing its own source of a vital raw material to de-risk its clinical and commercial strategy for a key pipeline asset.
ImmunityBio will pay a $60 million upfront fee for the exclusive U.S. licensing rights. The company's market capitalization is approximately $3.2 billion. The NMIBC treatment market is currently valued at $380 million annually but is projected for substantial growth.
Merck's BCG vaccine, the current standard of care, generated $194 million in sales in the first quarter of 2026. The Tokyo-172 strain is distinct from Merck's TICE strain and is noted in scientific literature for its high immunogenicity. A Phase 3 trial of ImmunityBio's N-803 plus BCG demonstrated a 71% complete response rate at 12 months, compared to historical rates of 40-50% for BCG monotherapy during periods of adequate supply.
This acquisition directly benefits ImmunityBio by vertically integrating its supply chain for a pivotal combination therapy. It removes a major regulatory and manufacturing overhang for the potential commercial launch of N-803. Sectors poised to gain include contract manufacturing organizations and ancillary diagnostic companies focused on bladder cancer monitoring.
The primary counter-argument is the significant capital outlay for a component that may face its own regulatory scrutiny from the FDA, which must approve the Tokyo strain for use in a new combination product. This risk is mitigated by the strain's long history of safe use in Japan.
Positioning flow has been cautiously optimistic. Options volume on IBRX has increased 30% over its 20-day average, with a focus on out-of-the-money calls expiring in late 2026. Short interest remains elevated at 18% of float, indicating a significant cohort of investors remains skeptical of the company's valuation.
The key immediate catalyst is the expected Prescription Drug User Fee Act (PDUFA) date for N-803 in bladder cancer, projected for Q4 2026. FDA approval would validate the strategic acquisition and trigger commercial rollout plans.
Investors should monitor ImmunityBio's cash burn rate, with the next earnings report scheduled for 12 August 2026. The company reported $250 million in cash and equivalents last quarter. The $60 million payment will draw significantly on these reserves.
Technical levels to watch for IBRX stock include a support zone at $12.50, its 50-day moving average, and resistance near $18, a level it has tested twice in the past six months. A break above $18 on high volume could signal renewed institutional confidence.
The acquisition aims to ensure a consistent supply of BCG for patients should ImmunityBio's combination therapy gain approval. Chronic shortages of the Merck product have left many patients with suboptimal treatment options. Securing the Tokyo strain provides a validated alternative source, potentially improving treatment access and outcomes for thousands of bladder cancer patients in the U.S.
Merck faces increased competitive pressure. While its TICE BCG vaccine is entrenched as the standard of care, ImmunityBio's combo therapy has shown superior efficacy in trials. ImmunityBio controlling its own BCG supply removes a dependency on its largest competitor and allows it to directly challenge Merck's market dominance in NMIBC treatment, potentially capturing significant market share.
The Tokyo-172 strain itself is not FDA-approved as a standalone drug. Regulatory approval will be sought specifically for its use within ImmunityBio's combination product, N-803 plus BCG. The FDA will require comprehensive data demonstrating the safety, efficacy, and consistent manufacturing of the combination, leveraging the existing body of evidence for the Tokyo strain's use internationally.
ImmunityBio's $60 million acquisition strategically secures its supply chain for a high-value oncology asset.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.